Abstract No : Abstract #915MO
Indication : Head & Neck Cancer
Intervention : Pembrolizumab + Chemotherapy
Company : Merck & Co.
Technology : PD-1 inhibitor + Chemo
Results:
Median study follow-up (March 25, 2020) was 46.2 mo for pembro vs E and 45.6 mo for pembro+C vs E. Pembro and pembro+C improved OS vs E in the CPS ≥20, CPS ≥1, and total pops (Table). Pembro 48-mo OS was 21.6%, 16.7%, and 15.4% in the CPS ≥20, CPS ≥1, and total pops, respectively, vs 8.0%, 5.9%, and 6.6% for E. Pembro+C 48-mo OS was 28.6%, 21.8%, and 19.4% in the CPS ≥20, CPS ≥1, and total pops, respectively, vs 6.6%, 4.1%, and 4.5% for E. OS, PFS, ORR, and DOR data are shown in the table. Treatment-related grade 3-5 AEs: 17.0% for pembro, 71.7% for pembro+C, and 69.3% for E. In all, 11 pts (pembro, 6; pembro+C, 5) received a secondcourse of pembro; ORR for second course was 36.4% (CR, 1; PR, 3)
Conclusion:
Long-term follow-up confirmed the statistically significant improvement in OS established at the protocol-specified interim and final analyses for pembro vs E in pts with PD-L1 CPS ≥20 and CPS ≥1 and for pembro+C vs E in pts with PD-L1 CPS ≥20 and CPS ≥1, and total pop. Safety was favorable for pembro vs E and comparable for pembro+C vs E
